In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Precision Therapeutics raises $43mm in new financing round

Executive Summary

Precision Therapeutics (develops tests that help predict drug response) raised $43mm in an undisclosed venture round led by new investor Longitude Venture Partners. Returning backers Adams Capital Management, Quaker BioVentures, Birchmere Ventures, Techno Venture Management, and Draper Triangle Ventures also participated. Precision will use the funds to develop and commercialize its ChemoFx drug response marker test for chemotherapy patients.
Deal Industry
  • Biotechnology
  • In Vitro Diagnostics
  • Pharmaceuticals
  • In Vitro Diagnostics
    • Chemistry, Immunoassay
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies